PROPHYLACTIC NAPROXEN OR LORATADINE FOR BONE PAIN IN PATIENTS WITH BREAST CANCER RECEIVING CHEMOTHERAPY AND PEGFILGRASTIM: A RANDOMIZED, PHASE 2 STUDY (NOLAN) AMGEN 20110147; NCT 01712009.

被引：0
|
作者：
Guinigundo, Andrew S. [1 ]
Maxwell, Cathy [2 ]
Vanni, Linda [3 ]
Watson, Holly [4 ]
Badre, Sejal [5 ]
Kirshner, Jeffrey J. [6 ]
机构：
[1] Oncol Hematol Care Inc, Cincinnati, OH USA
[2] Adv Med Specialties, Miami, FL USA
[3] Providence Hosp, Southfield, MI 48037 USA
[4] Amgen Inc, Global Dev, Thousand Oaks, CA 91320 USA
[5] Amgen Inc, Global Biostat Sci, Thousand Oaks, CA 91320 USA
[6] Hematol Oncol Associates Cent New York, East Syracuse, NY USA
来源：
ONCOLOGY NURSING FORUM | 2013年 / 40卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E429 / E429
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy
    Kahan, Zsuzsanna
    Grecea, Daniela
    Smakal, Martin
    Tjulandin, Sergei
    Bondarenko, Igor
    Perjesi, Luca
    Illes, Andras
    Horvat-Karajz, Karoly
    Aradi, Ildiko
    BMC CANCER, 2019, 19
  • [22] A randomized, multicenter pragmatic trial comparing bone pain from a single dose of pegfilgrastim to 5 doses of daily filgrastim in breast cancer patients receiving neoadjuvant/adjuvant chemotherapy (REaCT-5G)
    Ng, Terry L.
    Taljaard, Monica
    Savard, Marie-France
    Stober, Carol
    Nicholls, Stuart
    Vandermeer, Lisa
    Thavorn, Kednapa
    Hampel, Claudia
    Shamess, Jennifer
    Mills, Natalie
    Hilton, John F.
    Clemons, Mark
    CANCER RESEARCH, 2022, 82 (04)
  • [23] A Randomized, Placebo-Controlled Phase II Study Evaluating the Reduction of Neutropenia and Febrile Neutropenia in Patients With Colorectal Cancer Receiving Pegfilgrastim With Every-2-Week Chemotherapy
    Hecht, J. Randolph
    Pillai, Madhavan
    Gollard, Russell
    Heim, William
    Swan, Forrest
    Patel, Ravi
    Dreiling, Lyndah
    Mo, May
    Malik, Imtiaz
    CLINICAL COLORECTAL CANCER, 2010, 9 (02) : 95 - 101
  • [24] A Multicenter Randomized Phase II Study of KRN125 (Pegfilgrastim) to Determine the Optimal Dosage in Japanese Breast Cancer Patients Receiving TAC Treatment
    Masuda, N.
    Nakamura, S.
    Ito, Y.
    Tokuda, Y.
    Tamura, K.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S380 - S380
  • [25] Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy
    Kosaka, Yoshimasa
    Rai, Yoshiaki
    Masuda, Norikazu
    Takano, Toshimi
    Saeki, Toshiaki
    Nakamura, Seigo
    Shimazaki, Ryutaro
    Ito, Yoshinori
    Tokuda, Yutaka
    Tamura, Kazuo
    SUPPORTIVE CARE IN CANCER, 2015, 23 (04) : 1137 - 1143
  • [26] Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy
    Yoshimasa Kosaka
    Yoshiaki Rai
    Norikazu Masuda
    Toshimi Takano
    Toshiaki Saeki
    Seigo Nakamura
    Ryutaro Shimazaki
    Yoshinori Ito
    Yutaka Tokuda
    Kazuo Tamura
    Supportive Care in Cancer, 2015, 23 : 1137 - 1143
  • [27] Pegfilgrastim nearly abrogates occurrence of neutropenic events early in the course of chemotherapy: results of a phase 3, randomized, double-blind, placebo-controlled study of patients with breast cancer receiving docetaxel.
    Vogel, C
    Rader, M
    Tyulandin, S
    Wiens, B
    Neumann, T
    Carroll, R
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S198 - S199
  • [28] A randomized phase II study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy
    Yeo, W.
    Mo, F. K. F.
    Suen, J. J. S.
    Ho, W. M.
    Chan, S. L.
    Yeung, W. K.
    Lau, W.
    Lee, K. K. C.
    Kwan, W. H.
    Zee, B.
    EJC SUPPLEMENTS, 2008, 6 (07): : 198 - 198
  • [29] Efficacy and safety of RGB-02, a proposed biosimilar pegfilgrastim to prevent chemotherapy-induced neutropenia: Results of a randomized, double-blind, phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving docetaxel/doxorubicin
    Horvat-Karajz, K.
    Grecea, D.
    Smakal, M.
    Illes, A.
    Kahan, Z.
    ANNALS OF ONCOLOGY, 2017, 28
  • [30] A Randomized Phase 2 Study of a Loading Dose of Ibandronate in Patients with Bone Metastases from Breast Cancer.
    Ritchie, D. M.
    Bray, C.
    Canney, P.
    CANCER RESEARCH, 2011, 71
12345